MELVILLE, NY--(Marketwired - May 1, 2014) - The Long Island Capital Alliance ("LICA"), the leading non-profit capital formation and business development organization serving regional companies, today announced the presenting companies and panelists for its Biotech Capital Forum to be held on Friday, May 9, 2014. The capital forum is being held in collaboration with North Shore-LIJ Health System's Feinstein Institute for Medical Research and Cold Spring Harbor Laboratory in an effort to facilitate raising capital to accelerate the growth of biotech businesses on Long Island.
Seven local biotechnology companies will present their business plans to investors, including attendees from venture capital firms, investment banks, private equity firms, angel and other individual investors. Each of the companies LICA selected for presentation at the capital forum possesses unique technologies and catalysts for significant growth which will be attractive to investors.
"We are pleased to be collaborating for a second time with Cold Spring Harbor Laboratory and welcome The Feinstein Institute for Medical Research in participating in our Biotech Capital Forum," said Neil Kaufman, Chairman of LICA. "These two world-class research institutions have developed seven very promising companies which will present at our Biotech Capital Forum. The volume and magnitude of research being conducted there continues to produce compelling growth companies, enabling LICA to present its Biotech Capital Forum for the second consecutive year, and we hope to continue to do so annually. We are also excited to have an extraordinarily accomplished investor panel provide their insight on these presenting companies and on biotech industry investment trends."
Biotech Capital Forum on May 9, 2014 - Participants
Panel of Investors
The following investment professionals will participate in the investor panel at the Biotech Capital Forum:
Doug Jamison, Harris & Harris Group: Doug Jamison is Chairman and Chief Executive Officer of Harris & Harris Group (
James Ryan III, Scout Ventures: James Ryan is Controller at Scout Ventures, a technology seed and venture fund. In addition, he is the Founder and CEO of The IllumiFi Group, an 'Outsourced CFO' for entrepreneurial firms.
Joe Proto, Windham Venture Partners: Joe Proto is a founder and general partner of Windham Venture Partners, a leading life sciences technology venture capital firm. He also is Chairman and Chief Executive Officer of Transactis Inc., sits on the Board of Directors of BillMyParents, and is a limited partner and advisor in Metamorphic Ventures.
Steve Winick, Topspin Partners: Steve Winick is a principal of Topspin Partners, one of Long Island's leading venture capital firms. He presently serves as a Director of Thermolift, Inc., Celmatix, Inc., Setpoint Medical, Inc., Mirimus, Inc., GenDX, Inc. and Certerra, Inc.
ASOThera: Developing new therapies for orphan diseases based on technology developed at Cold Spring Harbor Laboratory and already proven by Big Pharma.
Autoimmune Therapeutics, Inc.: Developing orally-available drug candidates to treat autoimmune disease, with initial focus on rheumatoid arthritis, based on proprietary small molecule scaffolds and pharmaceutical leads that inhibit macrophage migration inhibitory factor.
Certerra, Inc.: Contract research organization specializing in central nervous system with technology based on single neuron-level monitoring of mammalian brains.
Cirrus Health: Electronic discharge system to improve doctor patient communications.
DepYMed: Joint venture between CSHL and Ohr Pharmaceuticals (
Envisagenics, Inc.: Big data software solution that significantly reduces uncertainty and time to market for drugs under development.
TheraSource, LLC: Developing protein/peptide-based drugs based on MFG-E8 for inflammatory diseases, including sepsis, hemorrhagic shock, ischemia/reperfusion-induced injury, stroke, acute radiation syndrome, rheumatoid arthritis, and inflammatory bowel disease.
LICA, in collaboration with The Feinstein Institute for Medical Research and Cold Spring Harbor Laboratory, is hosting the Biotech Capital Forum on Friday, May 9, 2014 from 8:00 a.m. to 11:00 a.m. at 68 South Service Road, Melville, NY. The capital forum provides an opportunity to meet capital providers, entrepreneurs, industry executives and businesses seeking capital, as well as to hear a panel of industry experts discuss financing alternatives for bio tech companies.
About the Long Island Capital Alliance
Since 1984, the Long Island Capital Alliance (www.licapital.org), formerly known as Long Island Venture Group, has been promoting business growth on Long Island. LICA seeks to create a productive and business-friendly environment that will afford area businesses access to the resources necessary to compete successfully in today's markets. LICA serves as a focal point for the exchange of ideas among new and existing business enterprises, successful entrepreneurs, investors, and service providers. Through quarterly capital forums and special meetings, LICA brings together members of the region's business community, and has been recognized as the place to turn to when small businesses need equity, debt, or other financing, or for investors to find an attractive investment opportunity.
LICA's mission is to encourage economic development on Long Island by facilitating capital formation for a broad range of companies in various industries, from early stage to mature, middle market, closely held and publicly-traded businesses. LICA accomplishes this primarily through education, networking, quarterly capital forums, periodic special educational meetings, and alliances with other regional organizations. LICA brings together members of the region's business community and serves as the finance arm for significant local business and organizations.
About The Feinstein Institute for Medical Research
Headquartered in Manhasset, NY, The Feinstein Institute for Medical Research is home to international scientific leaders in many areas including Parkinson's disease, Alzheimer's disease, psychiatric disorders, rheumatoid arthritis, lupus, sepsis, human genetics, pulmonary hypertension, leukemia, neuroimmunology, and medicinal chemistry. The Feinstein Institute, part of the North Shore-LIJ Health System, ranks in the top 6th percentile of all National Institutes of Health grants awarded to research centers. For more information, visit www.FeinsteinInstitute.org.
About Cold Spring Harbor Laboratory
Founded in 1890, Cold Spring Harbor Laboratory (CSHL) has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology. CSHL is ranked number one in the world by Thomson Reuters for impact of its research in molecular biology and genetics. The Laboratory has been home to eight Nobel Prize winners.
Today, CSHL's multidisciplinary scientific community is more than 600 researchers and technicians strong and its Meetings & Courses program hosts more than 12,000 scientists from around the world each year to its Long Island campus and its China center. Tens of thousands more benefit from the research, reviews, and ideas published in journals and books distributed internationally by CSHL Press. The Laboratory's education arm also includes a graduate school and programs for undergraduates as well as middle and high school students and teachers. CSHL is a private, not-for-profit institution on the north shore of Long Island. For more information, visit www.cshl.edu.
- Health Care Industry
- Venture Capital
- Cold Spring Harbor Laboratory
- Long Island